Energy restriction enhances therapeutic efficacy of the PPARγ agonist, rosiglitazone, through regulation of visceral fat gene expression

Diabetes, Obesity and Metabolism

Volumn 10, Issue 3, 2008, Pages 251-263

  Moore, G B T ^a   Pickavance, Lucy C ^b   Briscoe, C P ^a   Clapham, J C ^a   Buckingham, R E ^a   Wilding, J P H ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Dietary obesity; Epididymal white adipose tissue; Hyperphagia; Pair feeding; PPAR ; Rosiglitazone

Indexed keywords

ADIPOCYTOKINE; FATTY ACID; FATTY ACID BINDING PROTEIN; FATTY ACID SYNTHASE; FATTY ACID TRANSPORTER; HEXOKINASE; INSULIN; LEPTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RESISTIN; ROSIGLITAZONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ARTICLE; CALORIC RESTRICTION; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; FOOD INTAKE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HYPERPHAGIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPOLYSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 39049089411     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00697.x     Document Type: Article

References (57)

1. Wilding JP, Gilbey SG, Mannan M et al. Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats. J Endocrinol 1992; 132: 299-304.
2. Wilding JP, Gilbey SG, Jones PM et al. Dexfenfluramine treatment and hypothalamic neuropeptides in diet-induced obesity in rats. Peptides 1992; 13: 557-563.
3. Pickavance LC, Tadayyon M, Widdowson PS et al. Therapeutic index for rosiglitazone in dietary obese rats: Separation of efficacy and haemodilution. Br J Pharmacol 1999; 128: 1570-1576.
4. Pickavance LC, Buckingham RE, Wilding JP. Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia. Diabetes Obes Metab 2001; 3: 171-180.
5. Pickavance L, Brand CL, Wassermann K, Wilding JPH. The dual PPARα/ γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 2005; 144: 308-316.
6. Lazar MA. How obesity causes diabetes: Not a tall tale. Science 2005; 307: 373-375.
7. Campbell IW. The clinical significance of PPAR gamma agonism. Curr Mol Med 2005; 5: 349-363.
8. Kawai T, Takei I, Oguma Y et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 1999; 48: 1102-1107.
9. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999; 22: 288-293.
10. Larsen PJ, Jensen PB, Sorensen RV et al. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes 2003; 52: 2249-2259.
11. Guo L, Tabrizchi R. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol Therap 2006; 111: 145-173.
12. Dey D, Medicherla S, Neogi P et al. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism 2003; 52: 1012-1018.
13. Misra P, Chakrabarti R, Vikramadithyan RK et al. PAT5A: A partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. J Pharmacol Exp Ther 2003; 306: 763-771.
14. Rocchi S, Picard F, Vamecq J et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8: 737-747.
15. Das M, Gabriely I, Barzilai N. Caloric restriction, body fat and ageing in experimental models. Obes Rev 2004; 5: 13-19.
16. Widdowson PS, Upton R, Buckingham R et al. Inhibition of food response to intracerebroventricular injection of leptin is attenuated in rats with diet-induced obesity. Diabetes 1997; 46: 1782-1785.
17. Bustin, SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25: 169-193.
18. Moore GB, Himms-Hagen J, Harper ME, Clapham JC. Overexpression of UCP-3 in skeletal muscle of mice results in increased expression of mitochondrial thioesterase mRNA. Biochem Biophys Res Commun 2001; 283: 785-790.
19. Patel L, Pass I, Coxon P et al. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001; 11: 764-768.
20. Gasic S, Tian B, Green A. Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations. J Biol Chem 1999; 274: 6770-6775.
21. Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med 2001; 79: 30-47.
22. Hofmann C, Lorenz K, Braithwaite SS et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134: 264-270.
23. Moore GB, Chapman H, Holder JC et al. Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 2002; 286: 735-741.
24. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
25. Way JM, Gorgun CZ, Tong Q et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276: 25651-25653.
26. Maeda N, Takahashi M, Funahashi T et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
27. Gottschling-Zeller H, Rohrig K, Hauner H. Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia 2000; 43: 377-383.
28. Ihara H, Urano T, Takada A, Loskutoff DJ. Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones. FASEB J 2001; 15: 1233-1235.
29. Zirlik A, Leugers A, Lohrmann J et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 2004; 91: 674-682.
30. Choi KC, Ryu OH, Lee KW et al. Effect of PPAR-α and -γ agonist on the expression of visfatin, adiponectin, and TNF-α in visceral fat of OLETF rats. Biochem Biophys Res Comm 2005; 336: 747-753.
31. Martin G, Schoonjans K, Lefebvre AM et al. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997; 272: 28210-28217.
32. Motojima K, Passilly P, Peters JM et al. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J Biol Chem 1998; 273: 16710-16714.
33. Frohnert BI, Hui TY, Bernlohr DA. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J Biol Chem 1999; 274: 3970-3977.
34. Martin G, Schoonjans K, Staels B, Auwerx J. PPARgamma activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis 1998; 137 (Suppl.): S75-S80.
35. Sul HS, Wang D. Nutritional and hormonal regulation of enzymes in fat synthesis: Studies of fatty acid synthase and mitochondrial glycerol-3-phosphate acyltransferase gene transcription. Ann Rev Nutr 1998; 18: 331-351.
36. Sul HS, Latasa MJ, Moon Y, Kim KH. Regulation of the fatty acid synthase promoter by insulin. J Nutr 2000; 130: 315S-320S.
37. Storch J, Thumser AE. The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 2000; 1486: 28-44.
38. Aubert J, Champigny O, Saint-Marc P et al. Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells. Biochem Biophys Res Commun 1997; 238: 606-611.
39. Houseknecht KL, Vanden Heuvel JP, Moya-Camarena SY et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun 1998; 244: 678-682.
40. Murakami K, Tobe K, Ide T et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998; 47: 1841-1847.
41. Shimaya A, Kurosaki E, Shioduka K, Nakano et al. YM268 increases the glucose uptake, cell differentiation and mRNA expression of glucose transporter in 3T3-L1 adipocytes. Horm Metab Res 1998; 30: 543-548.
42. Zhang B, Graziano MP, Doebber TW et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem 1996; 271: 9455-9459.
43. Margareto J, Gomez-Ambrosi J, Marti A, Martinez JA. Time-dependent effects of a high-energy-yielding diet on the regulation of specific white adipose tissue genes. Biochem Biophys Res Commun 2001; 283: 6-11.
44. Pearson SL, Cawthorne MA, Clapham JC et al. The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats. Biochem Biophys Res Commun 1996; 229: 752-757.
45. Hotamisligil GS, Johnson RS, Distel RJ et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-1379.
46. Uysal KT, Scheja L, Wiesbrock SM et al. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000; 141: 3388-3396.
47. Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999; 40: 967-972.
48. Way JM, Harrington WW, Brown KK et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2002; 142: 1269-1277.
49. Shearer J, Fueger PT, Bracy DP et al. Partial gene deletion of heart-type fatty acid-binding protein limits the severity of dietary-induced insulin resistance. Diabetes 2005; 54: 3133-3139.
50. Hertzel AV, Smith LA, Berg AH et al. Lipid metabolism and adipokine levels in fatty acid binding protein null and transgenic mice. Am J Physiol Endocrinol Metab 2006; 290: E814-E823.
51. Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 1999; 265: 265-271.
52. Rieusset J, Chambrier C, Bouzakri K et al. The expression of the p85alpha subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor gamma in human adipocytes. Diabetologia 2001; 44: 544-554.
53. Tang Y, Osawa H, Onuma H et al. Improvement in insulin resistance and the restoration of reduced phosphodiesterase 3B gene expression by pioglitazone in adipose tissue of obese diabetic KKAy mice. Diabetes 1999; 48: 1830-1835.
54. Tang Y, Osawa H, Onuma H et al. Phosphodiesterase 3B gene expression is enhanced in the liver but reduced in the adipose tissue of obese insulin resistant db/db mouse. Diabetes Res Clin Pract 2001; 54: 145-155.
55. Deng T, Shan S, Li P-P et al. Peroxisome proliferator-activated receptor-γ transcriptionally up-regulates hormone-sensitive lipase via the involvement of specificity protein-1. Endocrinology 2006;147: 875-884.
56. Postic C, Leturque A, Rencurel F et al. The effects of hyperinsulinemia and hyperglycemia on GLUT4 and hexokinase II mRNA and protein in rat skeletal muscle and adipose tissue. Diabetes 1993; 42: 922-929.
57. Printz RL, Koch S, Potter LR et al. Hexokinase II mRNA and gene structure, regulation by insulin, and evolution. J Biol Chem 1993; 268: 5209-5219.